

1684

A4

2. Marubayashi S, Matsuzaka C, Takeda A, et al. Fatal generalized acute graft-vs-host disease in a liver transplant recipient. *Transplantation* 1990; 50: 709.
3. Jamieson NV, Joysey V, Friend PJ, et al. Graft-vs.-host disease in solid organ transplantation. *Transplant Int.* 1991; 4: 67.
4. Bhaduri BR, Tan KC, Humphreys, et al. Graft-vs.-host disease after orthotopic liver transplantation in a child. *Transplant Proc* 1990; 22: 2378.
5. Roberts JP, Ascher NL, Lake J, et al. Graft-vs.-host disease after liver transplantation in humans: a report of four cases. *Hepatology* 1991; 14: 274.
6. Collins RH, Cooper B, Nikaein A, Klintmalm G, Fay JW. Graft-vs.-host disease in a liver transplant recipient. *Ann Int Med* 1992; 16: 391.
7. Deierhoi MH, Sollinger HW, Bozdech MJ, Belzer FO. Lethal graft-versus-host disease in a recipient of a pancreas-spleen transplant. *Transplantation* 1986; 41: 544.
8. Ramsey G, Nusbacher J, Starzl TE, Lindsay GD. Isohemagglutinins of graft origin after ABO-unmatched liver transplantation. *N Engl J Med* 1984; 311: 1167.
9. Friend PJ, McCarthy LJ, Filo RS, et al. Transmission of idiopathic (autoimmune) thrombocytopenic purpura by liver transplantation. *N Engl J Med* 1990; 323: 807.
10. Shaw BW Jr, Stratta RJ, Donovan JP, Langnas AN, Wood RP, Markin RJ. Postoperative care after liver transplantation. *Semin Liv Dis* 1989; 9: 202.
11. Chang H, Omitrovsky E, Hieter PA, et al. Identification of three new Ig-I like genes in man. *J Exp Med* 1986; 163: 425.
12. Southern EM. Detection of specific sequences among DNA fragments separated by gel electrophoresis. *J Mol Biol* 1975; 98: 503.
13. Wisecarver J, Shepherd S, Beisel K, Rubocki R. Serologic and molecular studies of two kindreds expressing recombinant HLA DR1/DR2 haplotypes. *Tissue Antigens* 1993; 41: 148.
14. Starzl TE, Demetris AJ, Murase N, Ildstad S, Ricordi C, Trucco M. Cell migration, chimerism, and graft acceptance. *Lancet* 1992; 339: 1579.
15. Ferrara JLM, Deeg HJ. Graft-versus-host disease. *N Engl J Med* 1991; 324: 667.
16. Via CS, Shanley JD, Shearer GM. Synergistic effect of murine cytomegalovirus on the induction of acute graft-vs-host disease involving MHC class I differences only. *J Immunol* 1990; 145: 3283.
17. McCarthy AL, Malik Peiris JS, Taylor CE, et al. Increase in severity of graft-versus-host disease by cytomegalovirus. *J Clin Pathol* 1993; 45: 542.
18. Bevan PC, Seaman M, Tolliday B, Chalmers DG. ABO haemolytic anaemia in transplanted patients. *Vox Sang* 1985; 49: 42.
19. Brecher ME, Moore SB, Reisner RK, Rakela J, Krom RF. Delayed hemolysis resulting from anti-A<sub>1</sub> after liver transplantation. *Am J Clin Pathol* 1989; 91: 232.
20. Salamon DJ, Ramsey G, Nusbacher J, Yang S, Starzl TE, Israel L. Anti-A production by a group O spleen transplanted to a group A recipient. *Vox Sang* 1985; 48: 309.
21. Gordon JM, Cohen P, Finlayson JS. Levels of anti-A and anti-B in commercial immune globulins. *Transfusion* 1980; 20: 90.
22. Brox AG, Coumoyer D, Sternbach M, Spurl G. Hemolytic anaemia following intravenous gamma globulin administration. *Am J Med* 1987; 82: 633.
23. Copelan EA, Strohm PL, Kennedy MS, Tutschka PJ. Hemolysis following intravenous immune globulin therapy. *Transfusion* 1986; 26: 410.
24. Rubocki RJ, Langnas AN, Shepherd S, et al. The origin of lymphocytes in donor-derived lymph nodes following combined liver/small bowel transplantation. *Transplantation* 1994; 57: 303.
25. Mazzaferro V, Andreola S, Regalia E, et al. Confirmation of graft-vs-host disease after liver transplantation by PCR HLA-typing. *Transplantation* 1993; 55: 425.
26. Herve P, Flesch M, Tigerghien P, et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor Alpha-A antibody for the treatment of refractory severe acute graft-vs.-host disease. *Blood* 1992; 79: 3362.
27. Cuthbert RJG, Phillips GL, Bennett MJ, et al. Anti-interleukin-2 receptor monoclonal antibody (BT 563) in the treatment of severe acute GVHD refractory to systemic corticosteroid therapy. *Bone Marrow Transplant* 1992; 10: 451.
28. Byers VS, Henslee PJ, Kernan NA, et al. Use of anti-pan T-lymphocyte ricin A chain immunotoxin in steroid resistant acute graft-versus-host disease. *Blood* 1990; 75: 1426.

Received 15 July 1993.

Accepted 21 October 1993.

## SUCCESSFUL LIVER TRANSPLANTATION FOR ISONIAZID-INDUCED HEPATIC FAILURE—A CASE REPORT<sup>1</sup>

A 6–12-month course of isoniazid (INH)\* has been recommended as prophylaxis against tuberculosis for individuals having an asymptomatic positive tuberculin skin test (1, 2). Isoniazid is known to cause an elevation of liver enzymes (3–5), which usually improves after INH is discontinued. However, INH may sometimes cause fatal hepatic necrosis (6–9).

Liver transplantation has been reported to be effective for drug-induced hepatic failure of multiple etiologies (10–13). However, there have been no reports of liver transplantation for INH-induced hepatic failure. We describe here the case of

a 16-year-old girl who developed hepatic failure following a 3-month course of INH use and was successfully treated with liver transplantation.

In September 1992, an otherwise healthy 16-year-old girl displayed a positive PPD skin test by routine examination, with a normal chest roentgenogram. She was placed on prophylactic doses of INH and pyridoxine. The INH was discontinued in late December, after she developed lethargy, weakness, and loss of appetite. In early January 1993, she was found to have scleral icterus, abnormal liver function tests, and coagulopathy (serum glutamic oxaloacetic transaminase 328 IU/L, glutamic pyruvic transaminase 313 IU/L, alkaline phosphatase 350 IU/L, total bilirubin 10.4 mg/dl, prothrombin time 20 sec, partial thromboplastin time 122 sec, ammonia 86  $\mu$ mol/L). She was hospitalized and was started on lactulose, neomycin, cimetidine and vitamin K.

After 2 weeks, her total bilirubin decreased to 8.4 mg/dl.

<sup>1</sup> This work was supported in part by research grants from the Veterans Administration and Project Grant DK-29961 from the National Institutes of Health, Bethesda, MD.

\* Abbreviation: INH, isoniazid.




FIGURE 1. Computerized tomography scan of the abdomen showing a diminished size heterogenous liver with calcified nodules.

serum glutamic oxaloacetic transaminase decreased to 203 IU/L, and ammonia decreased to 60  $\mu\text{mol/dl}$ ; however, her prothrombin time and partial thromboplastin time did not improve despite administration of fresh frozen plasma several times. She had not experienced episodes of bleeding or encephalopathy. She was transferred to our institution for possible liver transplantation. She had a firm liver without signs of portal hypertension. Computerized tomography scanning showed a diminished-size heterogeneous liver with calcified nodules (Fig. 1). There was no ascites or splenomegaly. Hepatitis A, B, C screens were negative. Serum alpha-1-antitrypsin, alpha-fetoprotein, copper, and ceruloplasmin levels were within normal ranges. Anti-smooth muscle, anti-DNA, anti-RNA, and antimicrosomal antibodies were negative. Cytomegalovirus and Epstein-Barr virus titers were negative. A chest roentgenogram was normal. Cultures from the sputa were negative.

In early February, she underwent orthotopic liver transplantation. Using the liver from a 10-year-old donor, the transplant was done with a transient portocaval shunt by the piggy-back method (14). An arterial graft was interposed between the infrarenal aorta and a small hepatic artery. The postoperative course was uneventful except for transient bleeding from a Roux-en-Y loop, which was treated with blood transfusion. Immunosuppression was with FK506 and steroids. Since her transplant, she has been on ethambutol and pyrazinamide continuously as antituberculosis prophylaxis. She had no episodes of rejection or infection and was discharged on the 13th postoperative day. She has had no respiratory symptoms and her chest roentgenogram has been normal during an 8-month follow-up.

The resected liver was 484.5 g and 16 $\times$ 6 $\times$ 7 cm in size (Fig.

2). It was red-brown, rubbery, firm, and shrunken, with massive areas of necrosis intermixed with yellowish nodules of intact liver tissue. Histologically, the liver had extensive necrosis mixed with areas of remaining islands of hepatocytes. There was extensive acute and chronic inflammation. There were some regenerating hepatocytes and many proliferating cholangioles. No significant fibrosis was seen.

Isoniazid hepatotoxicity is considered a hepatocellular hypersensitivity reaction that may cause diffuse hepatocellular necrosis (4). Initial elevation of transaminases occurs in 10–20% of patients undergoing INH therapy (15–17). Typically, this is remedied by discontinuation of INH. Although the mechanism of hepatic necrosis is unknown, once massive necrosis occurs the damage is irreversible and may be fatal. Mortality rates from hepatic failure are reported to be 23.2/100,000 or 57.9/100,000 (9, 18). In the present case, the resected liver showed massive necrosis, which was considered to be irreversible and fatal without liver transplantation.

Isoniazid hepatotoxicity resembles viral hepatitis and is diagnosed by ruling out other possible etiologies. In the present case, hepatitis screens and autoantibodies were negative. Alpha-1-antitrypsin, alpha-fetoprotein, copper, and ceruloplasmin levels were within normal ranges. The patient developed hepatic failure 3 months after the initiation of INH therapy.

Liver transplantation has been successful for drug-induced hepatic failure secondary to ketoconazole, paracetamol, flupixide, nonsteroidal antiinflammatory drugs, sulfasalamin, halothane, and salazopyrine (9–12). Severe irreversible cases of INH-induced hepatic failure reported previously did not undergo liver transplantation, although one patient




FIGURE 2. The resected liver: weight: 484.5 g, size: 16×10×7 cm. The liver is rubbery, firm, and shrunken. There are no areas of necrosis and small nodular areas of intact tissue.

died while waiting for transplantation (5). The present case is the first reported case of INH-induced hepatic failure to undergo successful liver transplantation.

It is important to differentiate an irreversible case from a reversible one. Coagulopathy and hyperammonemia, as well as elevated liver enzymes and bilirubin, which are resistant to medical therapy, should reflect irreversible hepatic necrosis requiring liver transplantation. Additionally, a small cirrhotic liver seen by computerized tomography scanning may reveal significant postnecrotic changes. Once these abnormalities occur, acute hepatic failure develops, with immediate need for transplantation.

After transplantation, prophylactic antituberculosis medication, exclusive of INH, was required in our patient who had not completed her initial course of therapy. Sinnott et al. (19) have recommended pyrazinamide for prophylaxis in the transplanted patient receiving cyclosporine-related immunosuppressives. We chose to treat our patient with a six-month course of the combination of pyrazinamide and ethambutol. The use of two second-line antituberculosis medications was chosen to enhance the mycobactericidal activity in this immunosuppressed patient.

In conclusion, liver transplantation should be considered for severe irreversible INH-induced hepatic failure.

TOSHIMICHI HASAGAWA\*  
 JORGE REYES  
 BAKR NOUR  
 ANDREAS G. TZAKIS

MICHAEL GREEN<sup>2</sup>  
 SATORU TODO  
 THOMAS E. STARZL<sup>3</sup>  
*The Pittsburgh Transplantation Institute  
 The Department of Surgery  
 The Department of Pediatric Infectious Diseases  
 University of Pittsburgh School of Medicine  
 Pittsburgh, Pennsylvania*

\* Address correspondence to Toshimichi Hasegawa, Department of Liver Transplantation Surgery, Children's Hospital of Pittsburgh, 3601 DeSoto St., Pittsburgh, PA 15213-2583.

<sup>1</sup> The Department of Pediatric Infectious Diseases.

<sup>3</sup> Address requests for reprints to Thomas E. Starzl, 500 Falk Clinic, 3601 Fifth Ave., Pittsburgh, PA 15261.

#### REFERENCES

1. Ferebee SH, Mount FW. Tuberculosis morbidity: a controlled trial of the prophylactic use of isoniazid and rifampin. *Am Rev Respir Dis* 1962; 85: 490.
2. Iseman MD, Miller B. If a tree falls in the forest: isoniazid and hepatitis. *Am Rev Respir Dis* 1989; 139: 1350.
3. Kumar A, Misra PK, Mehotra RAJ, Govil YC. Hepatic toxicity of rifampin and isoniazid. *Am Rev Respir Dis* 1989; 139: 1350.
4. Goldman C, Braman S. Isoniazid: a review of its clinical use and adverse effects. *Chest* 1972; 62: 71.
5. Nakajo MM, Rao M, Steiner P. Incidence of hepatitis in children receiving isoniazid chemoprophylaxis. *Am Rev Respir Dis* 1989; 8: 649.
6. Spyridis P, Sinaniotis C, Papadia I, Oreopoulos

- S, Papadatos C. Isoniazid liver injury during chemophylaxis in children. *Arch Dis Child* 1979; 54: 65.
7. Vanderhoof JA, Arment ME. Fatal hepatic necrosis due to isoniazid chemoprophylaxis in a 15-year-old girl. *J Pediatr* 1976; 88: 867.
  8. Gal AA, Klatt EC. Fatal isoniazid hepatitis in a child. *Pediatr Infect Dis* 1986; 5: 490.
  9. Snider DE, Cras GJ. Isoniazid-associated hepatitis deaths: a review of available information. *Am Rev Respir Dis* 1992; 145: 494.
  10. O'Grady JG, Wendon J, Tan KC, et al. Liver transplantation after paracetamol overdose. *Br J Med* 1991; 303: 221.
  11. Knight TE, Shikuma CY, Knight J. Ketokonazole-induced fulminant hepatitis necessitating liver transplantation. *J Am Acad Dermatol* 1991; 25: 398.
  12. Durand F, Samuel D, Bernuau J, et al. Fipexide-induced fulminant hepatitis: report of three cases with emergency liver transplantation. *J Hepatol* 1992; 15: 144.
  13. Isai H, Sheil AGR, McCaughan GW, et al. Fulminant hepatic failure and liver transplantation. *Transplant Proc* 1992; 24: 1475.
  14. Tzakis A, Todo S, Starzl TE. Orthotopic liver transplantation with preservation of the inferior vena cava. *Ann Surg* 1989; 210: 649.
  15. Byrd RB, Nelson R, Elliot RC. Isoniazid toxicity: a prospective study in secondary chemoprophylaxis. *J Am Med Assoc* 1972; 220: 1471.
  16. Beaudry PH, Brickman HF, Wise MB, MacDougall D. Liver enzyme disturbances during isoniazid chemoprophylaxis in children. *Am Rev Respir Dis* 1974; 110: 581.
  17. Mitchell JR, Zimmerman HJ, Ishak JG, et al. Isoniazid liver injury: clinical spectrum, pathology and probable pathogenesis. *Ann Int Med* 1976; 84: 181.
  18. Kopanoff DE, Snider DE, Cara GJ. Isoniazid-related hepatitis: a US Public Health Service cooperative surveillance study. *Am Rev Respir Dis* 1978; 117: 991.
  19. Sinnott JT, Emmanuel PJ. Mycobacterial infections in the transplant patient. *Semin Resp Infect* 1990; 5: 65.
- Received 29 September 1993.  
Accepted 21 October 1993.

### TUBERCULOSIS OF TWO CARDIAC ALLOGRAFTS IN ONE PATIENT

In the developed countries of the Western world, tuberculosis in solid organ recipients is an uncommon complication. There are some reports by a transplant group in Saudi Arabia (1-3) on tuberculosis in renal allografts; all of their patients responded to the classic tuberculostatic therapy. Also tuberculosis of the myocardium is a very rare disease (4). In the present case report we describe a patient who acquired tuberculosis infection in two consecutive heart transplants.

J.G., 45 years old, was first transplanted on September 26, 1985, because of terminal cardiomyopathy. The early postoperative course was uneventful. For the first ten days after transplantation, he received ATG (3 mg/kg/day), azathioprine (2 mg/kg/day), and cyclosporine. The maintenance immunosuppressive therapy consisted of cyclosporine and azathioprine. There were no signs of viral or bacterial infection. On January 14, 1986, a seroconversion occurred from anti-CMV IgM/IgG-negative to IgM-positive; as clinical symptoms were absent, no antiviral therapy was administered. The 10 endomyocardial biopsies (EB)\* obtained before March 1986 showed no rejection or mild rejections. In the EB of March 5, 1986, granulomas with giant cell formation were observed. Clinical examination, NMR imaging, and a tine test were negative—furthermore, anamnestic evaluation of the patient and the donor as well as the recipients of the other organs from the same multiorgan donor brought no additional evidence of tuberculosis, hence tuberculostatic measures did not appear to be indicated.

On December 4, 1986, routine coronary angiography revealed a slight, hemodynamically insignificant, stenosis of the right coronary artery. The same finding was obtained one year later. The only complications observed at follow-up were repeated renal insufficiency due to cyclosporine nephrotoxicity. By late summer 1989, the patient's general condition had deteriorated severely. The coronary angiogram of November 22, 1989, revealed stenosis of the circumflex artery, typical signs of small vessel disease of the left descending artery, and

occlusion of the right coronary artery. The function of the left ventricle was reduced, with an ejection fraction of 31%. The condition of the patient deteriorated accordingly, so he had to be retransplanted on July 25, 1990.

The excised heart, in addition to the angiographically verified coronary sclerosis and posterior wall infarction, showed multiple granulomas with caseous necrosis, interestingly only in the left ventricle. Pathohistologically, there were granulomas with macrophages, epithelioid cells and giant cells. No acid-resistant rods were identified. The pericardium as well as the remaining atria of the patient were not affected macroscopically. Bacterial smears from the pericardium and cultivation for *Mycobacterium tuberculosis* gave no evidence of infection.

In the postoperative course the patient developed severe renal insufficiency necessitating hemofiltration. The ventricular function was normal. NMR and CT imaging, performed to find further manifestations in other organs, yielded negative results. As immunosuppressive therapy he received methylprednisolone 125 mg every 8 hr on the first postoperative day, and thereafter cyclosporine (200 ng/ml blood, measured by HPLC), azathioprine 1 mg/kg/day, and low-dose steroids (0.2 mg/kg/day). Myambutol 3 × 400 mg and INH 2 × 300 mg were given as tuberculostatic therapy for only four weeks due to poor renal and rapidly deteriorating hepatic function. At one month after transplantation, EB showed moderate rejection, which was resolved by methylprednisolone 1 g for three days. The recovery was protracted, but nine weeks after the retransplantation the patient could be discharged.

From early spring 1991, J.G. complained once more of reduced performance, edema, and dyspnea. The coronary angiogram showed normal morphology, but LVEDP (32 mmHg) and pulmonary artery pressure (syst.: 70, diast.: 29, mean: 44 mmHg) were significantly elevated. The ejection fraction of the left ventricle was 32%. Echocardiography revealed that the contractility of both ventricles was severely reduced.

\* Abbreviation: EB, endomyocardial biopsy.